Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
After finishing at $13.45 in the prior trading day, Regenxbio Inc (NASDAQ: RGNX) closed at $13.26, down -1.41%. In other words, the price has decreased by -$1.41 from its previous closing price. On the day, 0.9 million shares were traded. RGNX stock price reached its highest trading level at $13.7999 during the session, while it also had its lowest trading level at $13.12.
Ratios:
Our goal is to gain a better understanding of RGNX by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.66 and its Current Ratio is at 2.66. In the meantime, Its Debt-to-Equity ratio is 1.66 whereas as Long-Term Debt/Eq ratio is at 1.35.
Upgrades & Downgrades
In the most recent recommendation for the company, Goldman on February 11, 2025, Downgraded its rating to Neutral and sets its target price to $14 from $38 previously.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Oct 09 ’25 when Simpson Curran sold 20,811 shares for $12.62 per share. The transaction valued at 262,635 led to the insider holds 216,162 shares of the business.
CURRAN M SIMPSON bought 20,811 shares of RGNX for $254,310 on Oct 09 ’25. On Sep 29 ’25, another insider, Simpson Curran, who serves as the Chief Executive Officer of the company, sold 7,624 shares for $10.03 each. As a result, the insider received 76,469 and left with 236,973 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RGNX now has a Market Capitalization of 671262144 and an Enterprise Value of 665197120. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.16 while its Price-to-Book (P/B) ratio in mrq is 4.16. Its current Enterprise Value per Revenue stands at 4.124 whereas that against EBITDA is -4.78.
Stock Price History:
The Beta on a monthly basis for RGNX is 1.13, which has changed by 0.33669353 over the last 52 weeks, in comparison to a change of 0.12934029 over the same period for the S&P500. Over the past 52 weeks, RGNX has reached a high of $13.93, while it has fallen to a 52-week low of $5.03. The 50-Day Moving Average of the stock is 16.51%, while the 200-Day Moving Average is calculated to be 46.88%.
Shares Statistics:
The stock has traded on average 559.77K shares per day over the past 3-months and 622410 shares per day over the last 10 days, according to various share statistics. A total of 50.62M shares are outstanding, with a floating share count of 46.13M. Insiders hold about 8.88% of the company’s shares, while institutions hold 81.45% stake in the company. Shares short for RGNX as of 1763078400 were 4741368 with a Short Ratio of 8.47, compared to 1760486400 on 4880756. Therefore, it implies a Short% of Shares Outstanding of 4741368 and a Short% of Float of 11.37.
Earnings Estimates
The market rating of Regenxbio Inc (RGNX) is currently shaped by the ongoing analysis conducted by 8.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$1.39, with high estimates of -$1.21 and low estimates of -$1.58.
Analysts are recommending an EPS of between -$1.67 and -$4.11 for the fiscal current year, implying an average EPS of -$3.26. EPS for the following year is -$1.87, with 8.0 analysts recommending between $1.61 and -$5.22.
Revenue Estimates
9 analysts predict $61.72M in revenue for. The current quarter. It ranges from a high estimate of $153.93M to a low estimate of $20M. As of. The current estimate, Regenxbio Inc’s year-ago sales were $21.21MFor the next quarter, 9 analysts are estimating revenue of $77.53M. There is a high estimate of $276.57M for the next quarter, whereas the lowest estimate is $21M.
A total of 10 analysts have provided revenue estimates for RGNX’s current fiscal year. The highest revenue estimate was $310.14M, while the lowest revenue estimate was $160.1M, resulting in an average revenue estimate of $202.26M. In the same quarter a year ago, actual revenue was $83.33MBased on 10 analysts’ estimates, the company’s revenue will be $280.26M in the next fiscal year. The high estimate is $407.6M and the low estimate is $140.63M.
